Its lead product candidate, rilparencel, is in Phase 3 and Phase 2 clinical studies in subjects with moderate to severe chronic kidney disease and diabetes. HC Wainwright & Co. initiated coverage with a Buy recommendation, positioning the company as a promising late-stage clinical player targeting a significant unmet medical need in nephrology.
Cyborg Score Rationale
The company has seen significant volatility following encouraging Phase 2 clinical trial outcomes for its REGEN-007 study. 4 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. Strong cash position with late-stage pipeline advancement offsets clinical trial execution risks.
Top Insights
Analyst HC Wainwright initiated coverage with a Buy recommendation and price target of $12.00, with average one-year price target revised to $6.85
Significant stock volatility following encouraging Phase 2 REGEN-007 trial outcomes for rilparencel in chronic kidney disease patients
ProKidney operates with 204 employees, maintaining lean operations typical of clinical-stage biotech firms
Market opportunity: Addressing moderate to severe chronic kidney disease with a cell therapy approach
Named Competitors
Advanced Renal Therapeutics — Nephrology-focused biotech company